UCB presents new epilepsy drug data at AES 2017

UCB is attending this week's American Epilepsy Society (AES) annual meeting, where it is sharing its latest epilepsy drug research insights.

Running from December 1st to 5th in Washington, DC, the conference is featuring a total of 25 abstracts from UCB's pipeline, including new data on therapies such as Vimpat and Briviact.

These will include results from a recent placebo-controlled trial assessing Vimpat as an adjunctive therapy in children aged four years and older and adolescents with uncontrolled focal seizures, plus updated data on the safety and tolerability of long-term treatment with adjunctive Briviact for focal seizures.

The company will also present preliminary data on the developmental drug candidates padsevonil and radiprodil, plus additional presentations including a social media survey assessing perceptions of patient information leaflets.

Additionally, UCB aims to use the conference to provide a platform for collaboration, ideation and exploration on how to exceed expectations when delivering care for people with epilepsy.

Jeff Wren, head of UCB's neurology patient value unit, said: "We have a longstanding heritage in epilepsy and take pride in the breadth and depth of our research we share each year at AES. This year is no exception."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.